Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis

American Journal of Gastroenterology

Volumn 113, Issue 8, 2018, Pages 1177-1186

  Bajaj, Jasmohan S ^a   Acharya, Chathur ^a   Fagan, Andrew ^a   White, Melanie B ^a   Gavis, Edith ^a   Heuman, Douglas M ^a   Hylemon, Phillip B ^a   Fuchs, Michael ^a   Puri, Puneet ^a   Schubert, Mitchell L ^a   Sanyal, Arun J ^a   Sterling, Richard K ^a   Stravitz, R Todd ^a   Siddiqui, Mohammad S ^a   Luketic, Velimir ^a   Lee, Hannah ^a   Sikaroodi, Masoumeh ^b   Gillevet, Patrick M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGE; ARTICLE; ASCITES; CLINICAL EVALUATION; CLINICAL OUTCOME; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABUSE; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTESTINE FLORA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION OVERUSE; MICROBIAL IDENTIFICATION; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; WITHDRAWAL SYNDROME; DRUG ADMINISTRATION; FECES; MICROBIOLOGY; MICROFLORA; VIRGINIA;

COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FECES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MICROBIOTA; MIDDLE AGED; PATIENT READMISSION; PROTON PUMP INHIBITORS; RISK FACTORS; VIRGINIA;

EID: 85048051773     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/s41395-018-0085-9     Document Type: Article

References (34)

1. Johnson DA, Katz PO, Armstrong D, et al. The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus. Drugs. 2017;77:547–61
2. Deshpande A, Pasupuleti V, Thota P, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28:235–42
3. Dam G, Vilstrup H, Watson H, et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64:1265–72
4. Cole HL, Pennycook S, Hayes PC. The impact of proton pump inhibitor therapy on patients with liver disease. Aliment Pharmacol Ther. 2016;44:1213–23
5. Tsai CF, Chen MH, Wang YP, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population study. Gastroenterology. 2017;152:134–41
6. Bajaj JS, Ratliff SM, Heuman DM, et al. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012;36:866–74
7. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol. 2009;104:1130–4
8. Bajaj JS, Cox IJ, Betrapally NS, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307:G951–7
9. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28:26–42
10. Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59–64
11. O’Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13:753–9
12. Bajaj JS, Reddy KR, Tandon P, et al. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016;64:200–8
13. Nava GM, Stappenbeck TS. Diversity of the autochthonous colonic microbiota. Gut Microbes. 2011;2:99–104
14. Patel VC, Shawcross DL. Salivary microbiota-immune profiling in cirrhosis: could this be the noninvasive strategy that will revolutionize prognostication in hepatology? Hepatology. 2015;62:1001–3
15. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940–7
16. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056s001019810s087lbl.pdf
17. Hamady M, Knight R. Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res. 2009;19:1141–52
18. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220–30
19. J Gregory Caporaso, Justin Kuczynski, Jesse Stombaugh, et al. Nature Methods, 2010; 10.1038/nmeth.f.303
20. Tapper EB. Challenge accepted: confronting readmissions for our patients with cirrhosis. Hepatology. 2016;64:26–8
21. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–8
22. Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149:883–5
23. Naito Y, Kashiwagi K, Takagi T, et al. Intestinal dysbiosis secondary to proton-pump inhibitor use. Digestion. 2018;97:195–204
24. Jackson MA, Goodrich JK, Maxan ME, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–56
25. Llorente C, Jepsen P, Inamine T, et al. Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. Nat Commun. 2017;8:837
26. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology. 2011;54:562–72
27. Dultz G, Piiper A, Zeuzem S, et al. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther. 2015;41:459–66
28. Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE. 2013;8:e60042
29. Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight. 2017;5: pii: 94416
30. Bajaj JS, Betrapally NS, Hylemon PB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015;62:1260–71
31. Bert F, Valla D, Moreau R, et al. Viridans group streptococci causing spontaneous bacterial peritonitis and bacteremia in patients with end-stage liver disease. Liver Transpl. 2008;14:710–1
32. Ahluwalia V, Betrapally NS, Hylemon PB, et al. Impaired gut-liver-brain axis in patients with cirrhosis. Sci Rep. 2016;6:26800
33. Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol. 2012;302:G168–75
34. Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54:2312–7